

Ⅲ. 平成21年度 研究成果の刊行に関する一覧表

IV. 研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
瀬崎ひとみ 熊田博光	C型肝炎型治療ガイドライン	銭谷幹男 八橋 弘 柴田 実	C型肝炎のベスト治療インターフェロンを中心に	医学書院	東京	2009	41-44
芥田憲夫 熊田博光	Q7 C型肝炎ウイルスのリアルタイムPCR法の導入でどのような点が有用となるのか？		肝臓病診療 こんなときどうするQ&A	中外医学社	東京	2009	155-156
八辻寛美 熊田博光	Q16 HBV核酸アナログ製剤のbreakthroughにはどのように対処すればよいのか？		肝臓病診療 こんなときどうするQ&A	中外医学社	東京	2009	56-60
八辻寛美 熊田博光	Q17 一度はじめたHBV核酸アナログ製剤を終了することは可能か？		肝臓病診療 こんなときどうするQ&A	中外医学社	東京	2009	61-63
八辻寛美 熊田博光	Q18 非代償性肝硬変に対するHBV核酸アナログ製剤の投与は有効か？		肝臓病診療 こんなときどうするQ&A	中外医学社	東京	2009	65-69
芥田憲夫 熊田博光	肝疾患治療薬-B型・C型肝炎における抗ウイルス療法・抗炎症療法	堀 正二 菅野健太郎 門脇 孝 乾 賢一 林 昌洋	治療薬ハンドブック2009	じほう	東京	2009	501-505
鈴木文孝 熊田博光	B型慢性肝炎	菅野健太郎 上西 紀夫 井廻 道夫	消化器疾患最新の治療	南江堂	東京	2009	291-294
森脇久隆	肝硬変	山口 徹, 北原光夫, 福井次矢	今日の治療指針2009年版	医学書院	東京	2009年	399-401
森脇久隆	2. 病状・病態	河田純男, 佐々木裕	現場の疑問に答える肝臓病診療Q&A	中外医学社	東京	2009年	98-105
白木 亮, 福島秀樹, 森脇久隆	アミノ酸とその分画	Medical Practice編集委員会	臨床検査ガイド2009-2010	文光堂	東京	2009年	212-217
今村道雄, 茶山一彰	ヒト肝細胞キメラマウスを用いた肝炎ウイルス研究	田中正広	最新医学	最新医学社	大阪市	2009	144-149
今村道雄, 柘植雅貴, 茶山一彰	キメラマウス		Medical Prictice	文光堂	大阪市	2010	105-106

<p>积迎堂敏 向坂彰太郎</p>	<p>循環器疾患へのインターフェロン治療</p>	<p>銭谷幹男 八橋 弘 柴田 実</p>	<p>C型肝炎のベスト治療インターフェロンを中心に</p>	<p>医学書院</p>	<p>東京</p>	<p>2009</p>	<p>92-93</p>
<p>芥田憲夫 熊田博光</p>	<p>Q7 C型肝炎ウイルスのリアルタイムPCR法の導入でどのような点が有用となるのか?</p>		<p>肝臓病診療 こんなときどうするQ&A</p>	<p>中外医学社</p>	<p>東京</p>	<p>2009</p>	<p>155-156</p>
<p>芥田憲夫 熊田博光</p>	<p>肝疾患治療薬-B型・C型肝炎における抗ウイルス療法・抗炎症療法</p>	<p>堀 正二 菅野健太郎 門脇 孝 乾 賢一 林 昌洋</p>	<p>治療薬ハンドブック2009</p>	<p>じほう</p>	<p>東京</p>	<p>2009</p>	<p>501-505</p>
<p>清家正隆</p>	<p>肝・骨格筋・脂肪組織における脂質代謝からみたNAFLD/NASHの治療戦略を探る</p>	<p>清家正隆</p>	<p>分子消化器病 vol6</p>	<p>先端医学社</p>	<p>東京</p>	<p>2009</p>	<p>59-63</p>

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H.</u>	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J Clin Virol	47 (1)	76-78	2010
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, <u>Kumada H.</u>	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H.</u>	Development of HCC in patients receiving adefovir dipiroxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	In press	In press	2010
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, <u>Kumada H.</u>	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum alanine aminotransferase during lamivudine treatment in hepatitis B.	Hepatol Res	In press	In press	2010
<u>Kumada H.</u> , Okanou T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis B virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40(1)	1-7	2010
<u>Kumada H.</u> , Okanou T, Onji M, Moriwaki H, Izumi N, Tanaka E, Cyayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y.	Guidelines for the treatment of chronic hepatitis and cirrhosis induced by hepatitis C virus infection for the fiscal year 2008 in Japan.	Hepatol Res	40(1)	8-13	2010
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H.</u>	The efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	J Gastroenterol Hepatol	In press	In press	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis	Dig Dis Sci	In press	In press	2010
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, <u>Kumada H.</u>	A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response	J Med Virol	81	452-458	2009
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, <u>Kumada H.</u>	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil	Intervirol	51	385-393	2009
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.	J Med Virol	81	1032-1039	2009
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.	Hepatology	49	739-744	2009
Arase Y, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, <u>Kumada H.</u>	Combination Therapy of Peginterferon and Ribavirin for Hepatitis C Patients with Genotype 1b and Low-virus Load.	Int Med	48	253-258	2009
Arase Y, Fumitaka S, Ikeda K, <u>Kumada H.</u> , Tsuji H, Kobayashi T.	Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease.	J Gastroenterol	44	1064-1070	2009
Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, <u>kumada H.</u>	Necessities of interferon therapy in elderly patients with hepatitis C.	A J Med	122	479-486	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, Akuta N, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H.</u>	Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.	J Viral Hepatitis	16	437-443	2009
Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H.</u>	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin.	Hepatol Res	39	346-354	2009
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, <u>Kumada H.</u>	High serum Alpha Fetoprotein and Des-gamma-Carboxy Prothrombin Level Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular carcinoma.	Cancer	115	571-580	2009
Sezaki H, Suzuki F, Akuta N, Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H.</u>	An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with C virus genotype 1b in high viral loads.	Intervirology	52	43-48	2009
Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, <u>Kumada H.</u>	Poor Response to Pegylated Interferon and Ribavirin in Aged Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads.	Dig Dis Sci	54	1317-1324	2009
Suzuki F, Kobayashi M, <u>Kumada H.</u> , Miyakoshi H.	Correlation Between Serum Hepatitis B Virus Core-Related Antigen and Intrahepatic Covalently Closed Circular DNA in Chronic Hepatitis B Patients.	J Med Virol	81	27-33	2009
Hosaka T, Ikeda K, Kobayashi M, Kawamura Y, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, <u>Kumada H.</u>	Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.	Liver International	29	736-742	2009
Morihara D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Suzuki Y, Suzuki F, <u>Kumada H.</u>	Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus related cirrhosis and thrombocytopenia.	Hepatol Res	39	439-447	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, <u>Kumada H.</u>	Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?	J Gastroenterol Hepatol	24	429-435	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, <u>Kumada H.</u>	Predictive value of amino acid sequences of the core and NS 5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol	44	952-963	2009
Hoshida Y, S M.B. Nijiman, Kobayashi M, J A. Chan, J-P Brunet, D Y. Chiang, A Villanueva, P Newell, Ikeda K, Hashimoto M, Watanabe M, S Gabriel, S L. Freiedman, <u>Kumada H.</u> , J M. Llovet, T R. Golub.	Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.	Cancer Res	69 (18)	7385-7392	2009
Kobayashi H, Fujioka S, Kawaguchi M, <u>Kumada H.</u> , Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Daniel J. Tenny, Omata M.	Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B.	Hepatol Int	3	403-410	2009
Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, <u>Kumada H.</u> , Puseenam A, Sura T, Daigo Y, Chayama K, Chantratita W, Nakamura Y, Matsuda K.	A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.	Nat Gne	41 (5)	591-595	2009
Shindo M, Cyayama K, Mochida S, Toyota J, Tomita E, <u>Kumada H.</u> , Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M.	Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naïve Japanese adult patients with chronic hepatitis B: a dandomized double-blind, phase II clinical trial.	Hepatol Int	3	445-452	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Association of amino acid substitution pattern in core protein of hepatitis C virus Genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.	Intervirolgy	52	301-309	2009
Arase Y, Suzuki F, Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Yatsuji H, Hirakawa M, Kobayashi M, Saitou S, Ikeda K <u>Kumada H.</u>	The efficacy of interferon- β monotherapy for elderly patients with type C hepatitis of genotype 2.	Int Med	48	1337-1342	2009
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitou S, Ikeda K, Kobayashi M, <u>Kumada H.</u> , Kobayashi T.	Losartan reduces the onset of type2 diabetes in hypertensive Japanese patients with chronic hepatitis C.	J Med Virol	81	1584-1590	2009
Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, <u>Kumada H.</u>	Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino acid substitutions in HCV Core region as Predictors of Mortality after First Treatment	Intervirolgy	52	179-188	2009
Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, <u>Kumada H.</u>	Rapid loss hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.	Hepatol Res	39	1056-1063	2009
Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, <u>Kumada H.</u>	Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.	Scn J Gastroenterol	44	975-983	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
坪内博仁、熊田博光、清澤研道、持田智、坂井田功、田中榮司、市田隆文、溝上雅史、鈴木一幸、興芝眞彰、森脇久隆、日比紀文、林紀夫、國土典宏、藤澤知雄、石橋大海、菅原寧彦、八橋弘、井戸章雄、滝川康裕、井上和明、桶谷真、宇都浩文、中山伸朗、内義隆文、多田慎一郎、木曾真一、矢野公士、遠藤龍人、田中靖人、梅村武司、熊谷公太郎。	免疫抑制・化学療法により発症するB型肝炎対策－厚生労働省「難治性の肝・胆道疾患に関する調査研究班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療の標準化に関する研究」班合同報告	肝臓	51 (1)	38-42	2009
保坂哲也、鈴木文孝、小林正宏、平川美晴、川村祐介、八辻寛美、瀬崎ひとみ、芥田憲夫、鈴木義之、斉藤聡、荒瀬康司、池田健次、小林万利子、熊田博光。	核酸アナログ療法中のB型関連肝癌に対する肝癌再発予測マーカーとしてHBコア関連抗原の有用性	肝臓	50 (10)	588-589	2009
Gen Y, Yasui K, Zen K, Nakajima T, Tsuji K, Endo M, Mitsuyoshi H, Minami M, Itoh Y, Tanaka S, Taniwaki M, Arie S, <u>Okanoue T</u> , Yoshikawa T	A novel amplification target, ARHGAP5, promotes cell spreading and migration by negulating RhoA in Huh-7 hepatocellular carcinoma cells	Cancer Letters	275	27-34	2009
Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, <u>Okanoue T</u> , Tsubouchi H, Ishikawa H, Seriu T, Omata M	Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naïve Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase III clinical trial	Hepatol Int	3	445-452	2009
Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y, Mitsuyoshi H, Minami M, Mitsufuji S, Tanaka S, Itoh Y, Nakamura Y, Taniwaki M, Arie S, <u>Okanoue T</u> , Yoshikawa T	ERK5 is a Target for Gene Amplification at 17p11 and Promotes Cell Growth in Hepatocellular Carcinoma by Regulating Mitotic Entry	GENES, CHROMOSOMES & CANCER	48	109-120	2009
Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, <u>Okanoue T</u> , Sato M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwakaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Daniel J. Tenney, Omata M	Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naïve chronic hepatitis B	Hepatol Int	3	403-410	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Matsuura K, Tanaka Y, Hige S, Yamada G, Murakawa Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakuma S, <u>Okanoue T</u> , Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M	Distribution of Hepatitis B Virus Genotypes among patients with Chronic Infection in Japan Shifting toward an Increase of Genotype A	J.Clin.Microbiol.	47	1476-1483	2009
<u>Okanoue T</u> , Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study	J Gastroenterol	44	952-963	2009
Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, <u>Onji M</u>	Etiology of liver cirrhosis in Japan: a nationwide survey	J Gastroenterol	45	86-94	2010
Konishi I, Hiasa Y, Shigematsu S, Hirooka M, Furukawa S, Abe M, Matsuura B, Michitaka K, Horiike N, <u>Onji M</u>	Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus	Liver International	29	1194-1201	2009
Nagaki M, Shimizu M, Sugihara J, Tomita E, Sano C, Naiki T, Kimura K, Amano K, Sakai T, Ninomiya M, Kojima T, Katsumura N, Fujimoto M, <u>Moriwaki H.</u>	Extended treatment duration of peginterferon-alpha-2b plus rebavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.	Aliment Pharm Therap	30	343-351	2009
Kimura K, Nagaki M, Saio M, Hosoi A, Saeki T, Okuda Y, Kuwata K, <u>Moriwaki H</u> , Kakimi K.	Role of CD44 on CTL-induced acute liver injury in hepatitis B virus transgenic mice.	J Gastroentel	44	218-227	2009
Kimura K, Nagaki M, Matsuura T, <u>Moriwaki H</u> , Kakimi K.	Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury.	Hepatol Res	39	93-105	2009
Ito H, Ando K, Ishikawa T, Saito K, Takemura M, Imawari M, <u>Moriwaki H</u> , Seishima M.	Role of TNF-alpha produced by nonantigen-specific cells in a fulminant hepatitis mouse model.	J Immunol	182	391-397	2009
Yasuda Y, Shimizu M, Sakai H, Iwasa J, Kubota M, Adachi S, Osawa Y, Tsurumi H, Hara Y, <u>Moriwaki H.</u>	(-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.	Chem Biol Interact	182	159-164	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsukada Y, Nagaki M, Suetsugu A, Osawa Y, <u>Moriwaki H.</u>	Extracellular matrix is required for the survival and differentiation of transplanted hepatic progenitor cells.	Biochem Biophys Res Commun	381	733-737	2009
Ohtaki H, Ito H, Ando K, Ishikawa T, Hoshi M, Tanaka R, Osawa Y, Yokochi T, <u>Moriwaki H.</u> Saito K, Seishima M.	Interaction between LPS-induced NO production andIDO activity in mouse peritoneal cells in the presence of activated Valpha14 NKT cells.	Biochem Biophys Res Commun	389	229-234	2009
Ohtaki H, Ito H, Ando K, Ishikawa T, Saito K, Imawari M, Yokochi T, <u>Moriwaki H.</u> Seishima M.	Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes.	Biochem Biophys Res Commun	378	579-583	2009
<u>Izumi N.</u> Nishiguchi, Hino K, Suzuki F, Kumada K, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M.	Management of Hepatitis C: Consensus of Japan Society of Hepatology 2009	Hepatol Res	40	In press	2010
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, <u>Izumi N</u>	A Predictive Model of Response to Peginterferon Ribavirin in Chronic Hepatitis C using Classification and Regression Tree Analysis.	Hepatol Res	40	In press	2010
Itakura J, Kurosaki M, Itakura Y, Maekawa S, Asahina Y, <u>Izumi N.</u> Enomoto N.	Reproducibility and usability of chronic virus infection model using agent-based simulation: comparing with a mathematical model.	Biosystems		In press	2009
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga, M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, <u>Izumi N.</u> Tokunaga K, Mizokami M.	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.	Nat Genet.	41	1105-1109	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H.	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol.	44	952-963	2009
Kusakabe A, Tanaka Y, Mochida S, Nakayama N, Inoue K, Sata M, Isoda N, Kang J. H, Sumino Y, Yatsushashi H, Takikawa Y, Kaneko S, Yamada G, Karino Y, Tanaka E, Kato J, Sakaida I, Izumi N, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M	Case-control study for the identification of virological factors associated with fulminant hepatitis B.	Hepatol Res	39	648-656	2009
Matsumoto A, Tanaka E	Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns (reply).	Hepatology	49	2125	2009
Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M	Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A.	J Clin Microbiol	47	1476-1483	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol	44	952-963	2009
Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, Tanaka E, Kakizaki S, Takagi H, Hiasa Y, Onji M, Aoyagi Y	Fucosylated Fraction of Alpha-Fetoprotein as a Predictor of Prognosis in Patients with Hepatocellular Carcinoma After Curative Treatment.	Dig Dis Sci			2009
Noda I, Kitamoto M, Nakahara H, Hayashi R, Okimoto T, Monzen Y, Yamada H, Imagawa M, Hiraga N, Tanaka J, Chayama K	Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus.	J Gastroenterol	45	105-112	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hiraga N, Imamura M, Hatakeyama T, Kitamura S, Mitsui F, Tanaka S, Tsuge M, Takahashi S, Abe H, Maekawa T, Ochi H, Tateno C, Yoshizato K, Wakita T, <u>Chayama K.</u>	Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice.	J Hepatol	51 (6)	1046-54	2009
Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, <u>Chayama K.</u>	Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.	J Clin Invest	119 (11)	3226-3235	2009
Abe H, Ochi H, Maekawa T, Hatakeyama T, Tsuge M, Kitamura S, Kimura T, Miki D, Mitsui F, Hiraga N, Imamura M, Fujimoto Y, Takahashi S, Nakamura Y, Kumada H, <u>Chayama K.</u>	Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection.	Hepatol Res	39	1159-1168	2009
Shindo M, <u>Chayama K.</u> , Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M.	Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial.	Hepatol Int	3	445-452	2009
Kodama H, Aikata H, Takaki S, Azakami T, Katamura Y, Kawaoka T, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Toyota N, Ito K, <u>Chayama K.</u>	Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices.	Eur J Radiol	In press		2010
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, <u>Chayama K.</u> Yoshioka K, Izumi N, Akuta N, Kumada H.	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol	44 (9)	952-963	2009
Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, Ushitora Y, Ohira M, Banshodani M, Tashiro H, Itamoto T, Asahara T, Imamura M, Takahashi S, <u>Chayama K.</u> Ohdan H.	Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness.	Transpl Int.	22 (8)	805-813	2009
Yotsuyanagi H, Kikuchi Y, Tsukada K, Nishida K, Kato M, Sakai H, Takamatsu J, Hige S, <u>Chayama K.</u> Moriya K, Koike K.	Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: a retrospective multicenter analysis.	Hepatol Res	39 (7)	657-663	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K, <u>Chayama K.</u>	Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.	Cardiovasc Intervent Radiol	32 (4)	687-694	2009
Noguchi C, Imamura M, Tsuge M, Hiraga N, Mori N, Miki D, Kimura T, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Tateno C, Yoshizato K, <u>Chayama K.</u>	G-to-A hypermutation in hepatitis B virus (HBV) and clinical course of patients with chronic HBV infection.	J Infect Dis	199 (11)	1599-1607	2009
Nabeshima Y, Tazuma S, Kanno K, Hyogo H, <u>Chayama K.</u>	Deletion of angiotensin II type I receptor reduces hepatic steatosis.	J Hepatol.	50 (6)	1226-1235.	2009
Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, <u>Chayama K.</u> Vaillant A, Liang TJ.	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry.	Gastroenterolog	137 (2)	673-681	2009
Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, Puseenam A, Sura T, Daigo Y, <u>Chayama K.</u> Chantratita W, Nakamura Y, Matsuda K.	A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.	Nat Ganet	41 (5)	591-595	2009
Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, <u>Chayama K.</u>	Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.	J Gastroenterol.	44 (5)	492-502	2009
Mitsui F, Aikata H, Azakami T, Katamura Y, Kimura T, Kawaoka T, Saneto H, Takaki S, Hiraga N, Tsuge M, Waki K, Hiramatsu A, Imamura M, Kawakami Y, Takahashi S, Arihiro K, <u>Chayama K.</u>	The first Japanese case of COACH syndrome.	Hepatol Res.	39(3)	318-323	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tsuji K, Kawakami Y, Aimitsu S, Kohno H, Aisaka Y, Kimura S, Nagata S, Ohgoshi H, Kitamoto M, Hidaka T, Kawakami H, Nakanishi T, <u>Chayama K.</u>	Predicting the response to 48-week combination therapy with peginterferon alpha-2b plus ribavirin from the estimated HCV RNA load index after negative serum change in genotype 1b hepatitis C patients.	Hepatol Res.	39 (6)	531-538	2009
Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, <u>Chayama K.</u> Hiroshima Liver Study Group.	Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.	J Med Virol.	81 (4)	640-649	2009
Tsukada H, Ochi H, Maekawa T, Abe H, Fujimoto Y, Tsuge M, Takahashi H, Kumada H, Kamatani N, Nakamura Y, <u>Chayama K.</u> the Hiroshima Liver Study Group, and Toranomon Hospital.	A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C.	Gastroenterology.	136 (5)	1796-1805	2009
Kawaoka T, Aikata H, Takaki S, Uka K, Azakami T, Saneto H, Jeong SC, Kawakami Y, Takahashi S, Toyota N, Ito K, Hirokawa Y, <u>Chayama K.</u>	FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma.	Hepatol Res.	39 (2)	134-142	2009
Katamura Y, Aikata H, Kimura Y, Azakami T, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, <u>Chayama K.</u>	Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient.	Hepatol Res.	39 (4)	415-420	2009
Ohira M, Ishifuro M, Ide K, Irei T, Tashiro H, Itamoto T, Ito K, <u>Chayama K.</u> Asahara T, Ohdan H.	Significant correlation between spleen volume and thrombocytopenia in liver transplant patients: a concept for predicting persistent thrombocytopenia.	Liver Transpl.	15 (2)	208-215	2009
Kodama H, Aikata H, Takaki S, Takahashi S, Toyota N, Ito K, <u>Chayama K.</u>	Evaluation of patients with esophageal varices after endoscopic injection sclerotherapy using multiplanar reconstruction MDCT images.	AJR Am J Roentgenol.	192 (1)	122-130	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
早田哲郎、西澤新也、森原大輔、横山圭二、櫻井邦俊、上田秀一、坂本雅晴、阿南章、竹山康章、入江真、岩田郁、釈迦堂敏、佐々木秀法、高松泰、向坂彰太郎	免疫抑制・化学療法によるB型肝炎ウイルス再活性化とその対策	福岡大学医学紀要	36 (4)	235-241	2009
Hiramatsu N, Oze T, Yakushijin T, Inoue Y, Igura T, Mochizuki K, Imanaka K, Kaneko A, Oshita M, Hagiwara H, Mita E, Nagase T, Ito T, Inui Y, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa k, Kiso S, Kanto T, Kasahara A, <u>Takehara T</u> , Hayashi N	Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin	Journal of Viral Hepatitis	16	586-594	2009
Oze T, Hiramatsu N, Yakushijin T, Kurokawa M, Igura T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Hijioka T, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Yoshida Y, Tatsumi T, Ohkawa K, Kiso S, Kanto T, Kasahara A, <u>Takehara T</u> , Hayashi N	Pegylated interferon alpha-2a (Peg-IFN α -2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α -2b Plus ribavirin	Journal of Viral Hepatitis	16	578-585	2009
Suzuki F, <u>Akuta N</u> , Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.	J Clin Virol	47 (1)	76-78	2010
Kobayashi M, Suzuki F, <u>Akuta N</u> , Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b.	J Med Virol	82	41-48	2010
Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, <u>Akuta N</u> , Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Development of HCC in patients receiving adefovir dipiroxil for lamivudine-resistant hepatitis B virus mutants.	Hepatol Res	In press	In press	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kobayashi M, Suzuki F, <u>Akuta N</u> , Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum alanine aminotransferase during lamivudine treatment in hepatitis B.	Hepatol Res	In press	In press	2010
Suzuki F, <u>Akuta N</u> , Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	The efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.	J Gastroenterol Hepatol	In press	In press	2010
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H	Association of HLA-DR14 with Treatment Response in Japanese Patients with Autoimmune Hepatitis	Dig Dis Sci	In press	In press	2010
<u>Akuta N</u> , Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response	J Med Virol	81	452-458	2009
<u>Akuta N</u> , Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.	Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil	Intervirol	51	385-393	2009
<u>Akuta N</u> , Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.	J Med Virol	81	1032-1039	2009
Arase Y, Suzuki F, Suzuki Y, <u>Akuta N</u> , Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.	Hepatology	49	739-744	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Arase Y, Suzuki F, <u>Akuta N</u> , Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Hosaka T, Yatsuji H, Hirakawa M, Saitoh S, Ikeda K, Kobayashi M, Kumada H.	Combination Therapy of Peginterferon and Ribavirin for Hepatitis C Patients with Genotype 1b and Low-virus Load.	Int Med	48	253-258	2009
Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H.	Necessities of interferon therapy in elderly patients with hepatitis C.	A J Med	122	479-486	2009
Ikeda K, Kobayashi M, Someya T, Saitoh S, Hosaka T, <u>Akuta N</u> , Suzuki F, Suzuki Y, Arase Y, Kumada H.	Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.	J Viral Hepatitis	16	437-443	2009
Kawamura Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, Saitoh S, Yatsuji H, Sezaki H, <u>Akuta N</u> , Suzuki F, Suzuki Y, Arase Y, Kumada H.	Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin.	Hepatol Res	39	346-354	2009
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, <u>Akuta N</u> , Suzuki F, Suzuki Y, Saitoh S, Arase Y, Kumada H.	High serum Alpha Fetoprotein and Des-gamma-Carboxy Prothrombin Level Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular carcinoma.	Cancer	115	571-580	2009
Sezaki H, Suzuki F, <u>Akuta N</u> , Yatsuji H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with C virus genotype 1b in high viral loads.	Intervirolgy	52	43-48	2009
Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H.	Poor Response to Pegylated Interferon and Ribavirin in Aged Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads.	Dig Dis Sci	54	1317-1324	2009
Suzuki F, Kobayashi M, Kumada H, Miyakoshi H.	Correlation Between Serum Hepatitis B Virus Core-Related Antigen and Intrahepatic Covalently Closed Circular DNA Chronic Hepatitis B Patients.	J Med Virol	81	27-33	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hosaka T, Ikeda K, Kobayashi M, Kawamura Y, Sezaki H, <u>Akuta N</u> , Suzuki F, Suzuki Y, Arase Y, Kumada H.	Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma.	Liver International	29	736-742	2009
Morihara D, Kobayashi M, Ikeda K, Kawamura Y, Saneto H, Yatsuji H, Hosaka T, Sezaki H, <u>Akuta N</u> , Suzuki Y, Suzuki F, Kumada H.	Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus related cirrhosis and thrombocytopenia.	Hepatology Res	39	439-447	2009
Suzuki Y, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, <u>Akuta N</u> , Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Miyakawa Y, Kumada H.	Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?	J Gastroenterol Hepatol	24	429-435	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, <u>Akuta N</u> , Kumada H.	Predictive value of amino acid sequences of the core and NS 5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol	44	952-963	2009
<u>Akuta N</u> , Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Association of amino acid substitution pattern in core protein of hepatitis C virus Genotype 2a high viral load and virological response to interferon- α /ribavirin combination therapy.	Intervirology	52	301-309	2009
Arase Y, Suzuki F, Sezaki H, Kawamura Y, Suzuki Y, Kobayashi M, <u>Akuta N</u> , Hosaka T, Yatsuji H, Hirakawa M, Kobayashi M, Saitou S, Ikeda K, Kumada H.	The efficacy of interferon- β monotherapy for elderly patients with type C hepatitis of genotype 2.	Int Med	48	1337-1342	2009
Arase Y, Suzuki F, Suzuki Y, <u>Akuta N</u> , Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Saitou S, Ikeda K, Kobayashi M, Kumada H, Kobayashi T.	Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C.	J Med Virol	81	1584-1590	2009
Ogura S, <u>Akuta N</u> , Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.	Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino acid substitutions in HCV Core region as Predictors of Mortality after First Treatment	Intervirology	52	179-188	2009

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Suzuki F, <u>Akuta N</u> , Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H.	Rapid loss hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.	Hepatol Res	39	1056-1063	2009
Kobayashi M, Suzuki F, <u>Akuta N</u> , Hosaka T, Sezaki H, Yatsuji H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Kumada H.	Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels.	Scn J Gastroenterol	44	975-983	2009
保坂哲也、鈴木文孝、小林正宏、平川美晴、川村祐介、八辻寛美、瀬崎ひとみ、芥田憲夫、鈴木義之、斉藤聡、荒瀬康司、池田健次、小林万利子、熊田博光。	核酸アナログ療法中のB型関連肝臓癌に対する肝臓再発予測マーカーとしてHBコア関連抗原の有用性	肝臓	50 (10)	588-592	2009
<u>Nomura H</u> , Miyagi Y, Tanimoto H, Ishibashi H.	Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C.	J Viral Hepat.	16	346-351	2009.
<u>Nomura H</u> , Miyagi Y, Tanimoto H, Higashi M, Ishibashi H.	Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.	J Gastroenterol	44	338-345	2009
Kawabe N, Hashimoto S, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Komura N, Kobayashi K, <u>Yoshioka K</u> .	The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection.	J Gastroenterol	44	751-756	2009
Nitta Y, Kawabe N, Hashimoto S, Harata M, Komura N, Kobayashi K, Arima Y, Shimazaki H, Nakano T, Murao M, Ichino N, Osakabe K, Aoki H, Hosoe Y, Sugiyama H, Nishikawa T, <u>Yoshioka K</u> .	Liver stiffness measured by transient elastography correlates with fibrosis area in liver biopsy in patients with chronic hepatitis C.	Hepatol Res	39	675-684	2009